Drugs / Trontinemab
Trontinemab
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04023994 | Aug 2019 → Jul 2020 | Alzheimer disease | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04639050 | Mar 2021 → Jul 2027 expected | Alzheimer disease | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07170150 | Nov 2025 → Jun 2028 expected | Alzheimer disease | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 3 | NCT07169578 | Sep 2025 → Jun 2028 expected | Alzheimer disease | Hoffmann-La Roche | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-07-28 | Hoffmann-La Roche | Results Roche presents new insights in Alzheimer’s disease research across its diagnostics and pharmaceutical portfolios at AAIC roche.com ↗
Trontinemab’s Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E remaining <5% |
| 2025-04-03 | Hoffmann-La Roche | Results Roche presents novel therapeutic and diagnostic advancements in Alzheimer’s at AD/PD 2025 roche.com ↗
Highlights included presentations from the ongoing trontinemab Phase Ib/IIa Brainshuttle™ AD study demonstrating dose-dependent rapid amyloid depletion from the brain and the potential of the Elecsys® pTau181 plasma test to rule out amyloid pathology. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-07-28 | Hoffmann-La Roche | Roche presents new insights in Alzheimer’s disease research across its diagnostics and pharmaceutical portfolios at AAIC roche.com ↗ |
| 2025-04-03 | Hoffmann-La Roche | Roche presents novel therapeutic and diagnostic advancements in Alzheimer’s at AD/PD 2025 roche.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trontinemab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07170150 ↗ |
| Known as | RG-6102 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095377 ↗ |
| Known as | RO7126209 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04639050 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5095377 ↗ |
| Route | Intravenous | “single-ascending intravenous doses of RO7126209” NCT04023994 ↗ |